Laboratoire français du Fractionnement et des Biotechnologies
Laboratoire français du Fractionnement et des Biotechnologies (LFB) is a leading biopharmaceutical company headquartered in France, with significant operations across Europe and North America. Founded in 1994, LFB has established itself as a key player in the biopharmaceutical industry, specialising in the development and production of innovative therapies derived from human plasma. LFB's core offerings include a range of plasma-derived medicinal products, particularly in the fields of immunology, haematology, and critical care. What sets LFB apart is its commitment to high-quality standards and advanced biotechnological processes, ensuring the safety and efficacy of its products. With a strong market position, LFB has achieved notable milestones, including the expansion of its product portfolio and global reach, solidifying its reputation as a trusted provider in the biopharmaceutical sector.
DitchCarbon Score
How does Laboratoire français du Fractionnement et des Biotechnologies's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Laboratoire français du Fractionnement et des Biotechnologies's score of 23 is lower than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Laboratoire français du Fractionnement et des Biotechnologies's reported carbon emissions
Laboratoire français du Fractionnement et des Biotechnologies currently does not report any carbon emissions data, as there are no available figures for kg CO2e emissions. Additionally, the organisation has not established any specific reduction targets or climate pledges. As a result, there is no information on their Scope 1, 2, or 3 emissions, nor any significant achievements in emissions reduction. The absence of data suggests that the company may still be in the early stages of developing its climate commitments or reporting practices. In the context of the biotechnology industry, it is increasingly important for organisations to set measurable climate goals and report emissions transparently to align with global sustainability efforts.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Laboratoire français du Fractionnement et des Biotechnologies is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
